Clinical Trial Update: Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update indicating completion of a Phase 1/2 safety study comparing PF582 with Lucentis in age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)
• PF582

Snippet

Sponsor: Pfenex, Inc | Conditions: Age Related Macular Degeneration (AMD) | Phase 1, Phase 2 | Status: COMPLETED